Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 62, Issue 2, 2003, Pages 79-86

  Sargin, Haluk ^a   Sargin, Mehmet ^a   Altuntaş, Yüksel ^b   Şengül, Ahmet M ^b   Orbay, Ekrem ^a   Seber, Selçuk ^b   Uçak, Sema ^b   Yayla, Ali ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Sisli Etfal Education/Res Hospital   (Turkey)

Author keywords

Intensive insulin treatment; Lispro insulin; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; STATISTICAL ANALYSIS; WEIGHT GAIN;

EID: 0142199871     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00167-0     Document Type: Article

References (24)

1. Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 20:1997;1822-1826.
2. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria, the DECODE study group, European Diabetes Epidemiology Group: diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 354:1999;617-621.
3. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Int. Med. 161:2001;397-405.
4. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 39:1996;1577-1583.
5. 1c. Diabetes Care. 23:2000;1236-1241.
6. Jovanovic L. Rationale for prevention and treatment of postprandial glucose-mediated toxicity. Endocrinologist. 9:1999;87-92.
7. 1c influenced more strongly by preprandial or postprandial glycemia in type 1 diabetes. Diabetes Care. 25:2002;1100-1101.
8. 1c interrelationships in type 2 diabetes. Diabetes Care. 24:2001;2023-2029.
9. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 43:1994;396-404.
10. Bolli G.B., Di Marchi R.D., Park G.D., Pramming S., Koivisto V.A. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 42:1999;1151-1167.
11. Anderson J.H., Brunelle R.L., Keohane P., et al. Mealtime treatment with insulin analog improves postprandial hyperlycemia and hypoglycaemia in patients with non-insulin-dependent diabetes mellitus. Arch. Int. Med. 157:1997;1249-1255.
12. Ross S.A., Zinman B., Campos R.V., Strack T. A comparative study of insulin Lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin. Invest. Med. 24:2001;292-298.
13. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197.
14. Torlone E., Pampanelli S., Lalli C., et al. Effects of short-acting analog [Lys(B28), pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care. 20:1997;1047-1048.
15. Trautmann M.E. Effect of the insulin analogue [Lys(B28), pro(B29)] on blood glucose control. Horm. Metab. Res. 26:1994;588-590.
16. Milicevic Z., Profozic J., Wyatt J., et al. Intramuscular injection of insulin Lispro or soluble human insulin: pharmacokinetics and glucodynamics in type 2 diabetes. Diabetic Med. 18:2001;562-566.
17. Heinemann L., Kapitza C., Starke A.A., Heise T. Time-action profile of the insulin analogue B28 Asp. Diabetic Med. 13:1996;683-684.
18. Roach P., Strack T., Arora V., Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin Lispro and insulin Lispro protamine suspension in patients with types 1 and 2 diabetes. IJCP. 55:2001;177-182.
19. Holleman F., Hoekstra J. Insulin Lispro. New Engl. J. Med. 17:1997;176-182.
20. Chase H.P., Lackspeiser T., et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycaemia in type 1 diabetes. Diabetes Care. 24:2001;4310-4314.
21. K. Karşidag, İ. Satman, N. Dinççag, et al., Comparison of metabolic control in IDDM with two different intensive regimens of [Lys (B28), Pro (B29)]-human insulin (Lispro) plus NPH insulin, Diabetologia (1996) S1, V39, PA222.
22. Hoffman R.M., Shah J.H., Wendel C.S., et al. Evaluating once-and twice-daily self-monitored blood glucose testing strategies for stable insulin-treated patients with type 2 diabetes: the diabetes outcomes in veterans study. Diabetes Care. 25:2002;1744-1748.
23. Heller S.R., Amiel S.A., Evans M.L., Kong M.F., Macdonald I.A., Peacey S.R. Does insulin Lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen. Diabetes Obes. Metab. 4:2002;106-112.
24. Mudaliar S.R.D., Edelman S.V. Intensive insulin therapy for patients with type 2 diabetes mellitus. LeRoith D., Taylor S.I., Olefsky J.M. Diabetes Mellitus, a Fundemental and Clinical Text. 2000;811-827 Lippincott Williams & Wilkins, Philadelphia.